Houlihan Lokey Advises Grünenthal GmbH

Houlihan Lokey is pleased to announce that Grünenthal GmbH (Grünenthal or the company) has successfully upsized and extended its existing €500 million revolving credit facility to a total amount of €600 million. The transaction was signed and closed in November 2024. Houlihan Lokey served as the exclusive financing advisor on this transaction.

Grünenthal is a science-based, fully integrated pharmaceutical company and is a global leader in pain management and related diseases. The company has a long track record of bringing innovative pain treatments and state-of-the-art technologies to patients. It is headquartered in Aachen, Germany, employs about 4,400 people and is present in 27 countries with affiliates in Europe, Latin America, and the U.S. Grünenthal’s products are available in approximately 100 countries.

Houlihan Lokey served as the exclusive financial advisor to Grünenthal.

RELATED: Pharmaceutical Services, Capital Markets